Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Kidney cancer: No advantage of adjuvant sunitinib or sorafenib.

Literature DB >> 27030525

Kidney cancer: No advantage of adjuvant sunitinib or sorafenib.

Louise Stone.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2016 PMID： 27030525 DOI： 10.1038/nrurol.2016.63

Source DB: PubMed Journal: Nat Rev Urol ISSN： 1759-4812 Impact factor: 14.432

× No keyword cloud information.

2 in total

1. Adjuvant therapy for renal-cell carcinoma: settled for now.

Authors: Stefan Duensing; Markus Hohenfellner
Journal: Lancet Date: 2016-03-09 Impact factor: 79.321

2. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Authors: Naomi B Haas; Judith Manola; Robert G Uzzo; Keith T Flaherty; Christopher G Wood; Christopher Kane; Michael Jewett; Janice P Dutcher; Michael B Atkins; Michael Pins; George Wilding; David Cella; Lynne Wagner; Surena Matin; Timothy M Kuzel; Wade J Sexton; Yu-Ning Wong; Toni K Choueiri; Roberto Pili; Igor Puzanov; Manish Kohli; Walter Stadler; Michael Carducci; Robert Coomes; Robert S DiPaola
Journal: Lancet Date: 2016-03-09 Impact factor: 79.321

2 in total

1 in total

1. Immune-related long non-coding RNAs can serve as prognostic biomarkers for clear cell renal cell carcinoma.

Authors: Cheng Shan Li; Zhang Ze Lu; Da Lang Fang; Wei Jie Zhou; Jie Wei
Journal: Transl Androl Urol Date: 2021-06

1 in total